B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up from $1. The company’s topline results from the Phase 2 SHIMMER study of CT1812 in patients with dementia with Lewy bodies exceeded expectations in terms of consistency and magnitude of treatment effect, the analyst tells investors in a research note. The firm says Cognition is “here to stay, even thrive now” on the back of these results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics upgraded to Buy from Neutral at B. Riley
- Cognition Therapeutics price target raised to $6 from $5 at H.C. Wainwright
- Cognition Therapeutics announces results in Phase 2 study of CT1812
- Cognition announces all participants completed final visit in SHIMMER study
- Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis